BigHat Biosciences is reimagining antibody discovery and engineering with an AI-first experimental platform that integrates a high-speed wet lab with machine learning to create better antibodies faster and undertake novel designs far beyond what’s possible today.
Location: United States, California, San Mateo
Employees: 11-50
Total raised: $94M
Founded date: 2019
Investors 7
| Date | Name | Website |
| - | Old Silver... | oldsilverv... |
| - | S32 | s32.com |
| - | Flucas Ven... | flucasvc.c... |
| - | 8VC | 8vc.com |
| - | Olima Vent... | olima.vc |
| 07.01.2022 | MBC BioLab... | mbcbiolabs... |
| - | Axial VC | axialvc.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.07.2022 | Series B | $75M | - |
| 10.02.2021 | Series A | $19M | - |
Mentions in press and media 15
| Date | Title | Description |
| 29.11.2022 | BigHat Biosciences Announces Research Collaboration with Merck | Collaboration leverages BigHat’s AI-enabled platform to expedite protein engineering to design and develop novel therapeutic candidates BigHat Biosciences, a biotechnology company with a machine learning-guided antibody discovery and develo... |
| 21.07.2022 | A first-time VC raised $2 million in 2 months to invest in women after Roe was overturned | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Erika Lucas wasn’t planning on launching a venture fund two months ago. Lucas, who runs mentorshi... |
| 21.07.2022 | BigHat Biosciences Raises $75 Million in Series B Funding to Design Safer, More Effective Antibodies | Capital will advance BigHat’s internal pipeline of therapeutics to patients, expand platform capacity 10-fold, and accelerate strategic partnerships BigHat Biosciences, a biotechnology company developing safer, more effective antibody thera... |
| 20.07.2022 | BigHat Biosciences Raises $75M in Series B | SAN MATEO, CA, BigHat Biosciences, a biotechnology company, has raised a $75 million Series B funding round, led by Section 32. >> Click here for more funding data on BigHat Biosciences >> To export BigHat Biosciences fundin... |
| 20.07.2022 | BigHat Biosciences Raises USD75M Series B Funding Round | BigHat Biosciences, a San Mateo, CA-based biotechnology company developing antibody therapies for patients using machine learning and synthetic biology, raised a $75m Series B funding round. The round, which brings total funding to date to ... |
| 11.02.2021 | BigHat Biosciences Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments | Andreessen Horowitz-led investment fuels hiring and R&D for AI-enabled experimental platform that speeds the antibody engineering process BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody de... |
| 10.02.2021 | BigHat Biosciences bags $19M to 'supercharge' antibody development | Monoclonal antibodies have transformed the treatment of many diseases from cancer to autoimmune disorders. But the approach has its limitations, prompting scientists and companies to develop the next generation of antibody treatments and ot... |
| 10.02.2021 | BigHat Biosciences bags $19M to 'supercharge' antibody development | Monoclonal antibodies have transformed the treatment of many diseases from cancer to autoimmune disorders. But the approach has its limitations, prompting scientists and companies to develop the next generation of antibody treatments and ot... |
| 10.02.2021 | BigHat raises $19 million for an AI-powered antibody design platform | BigHat Biosciences, a protein therapeutics startup and developer of an AI-guided antibody design platform, today announced it has closed a $19 million series A round led by Andreessen Horowitz. A spokesperson told VentureBeat the funding wi... |
| 10.02.2021 | BigHat Biosciences : Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments | BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody design platform, today announced it has raised $19 million in an oversubscribed Series A funding round, led by Andreessen Horowitz, with partici... |
Show more